HAYA Therapeutics doses first cohort in Phase I HTX-001 trial
HAYA Therapeutics co-founder and CSO Daniel Blessing led HTX-001 research and development from concept to clinical trial.
21 May 2026
21 May 2026
HAYA Therapeutics co-founder and CSO Daniel Blessing led HTX-001 research and development from concept to clinical trial.
BMS will roll out Claude to over 30,000 employees, targeting three main areas for near-term impact.
The lightweight, at-home sensor records MJM, a validated biosignal for sleep evaluation.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.